129 related articles for article (PubMed ID: 35343875)
21. Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions.
Hosokawa K; Ohnishi T; Miura N; Sameshima H; Koide T; Tanaka KA; Maruyama I
Thromb Res; 2014 Jan; 133(1):66-72. PubMed ID: 24268424
[TBL] [Abstract][Full Text] [Related]
22. Selective Inhibition of PAR4 (Protease-Activated Receptor 4)-Mediated Platelet Activation by a Synthetic Nonanticoagulant Heparin Analog.
Lin YC; Ko YC; Hung SC; Lin YT; Lee JH; Tsai JY; Kung PH; Tsai MC; Chen YF; Wu CC
Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):694-703. PubMed ID: 30727756
[TBL] [Abstract][Full Text] [Related]
23. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin.
Kahn ML; Nakanishi-Matsui M; Shapiro MJ; Ishihara H; Coughlin SR
J Clin Invest; 1999 Mar; 103(6):879-87. PubMed ID: 10079109
[TBL] [Abstract][Full Text] [Related]
24. Protease-activating receptor-4 induces full platelet spreading on a fibrinogen matrix: involvement of ERK2 and p38 and Ca2+ mobilization.
Mazharian A; Roger S; Berrou E; Adam F; Kauskot A; Nurden P; Jandrot-Perrus M; Bryckaert M
J Biol Chem; 2007 Feb; 282(8):5478-87. PubMed ID: 17200114
[TBL] [Abstract][Full Text] [Related]
25. Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4-Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis.
Li S; Wang W; Lin L; Yang L; Cai Y; Yang X; Zhang T; Xiao C; Yan H; Gao N; Zhao J
Arterioscler Thromb Vasc Biol; 2023 Feb; 43(2):253-266. PubMed ID: 36519467
[TBL] [Abstract][Full Text] [Related]
26. In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist.
Kato Y; Kita Y; Nishio M; Hirasawa Y; Ito K; Yamanaka T; Motoyama Y; Seki J
Eur J Pharmacol; 1999 Nov; 384(2-3):197-202. PubMed ID: 10611442
[TBL] [Abstract][Full Text] [Related]
27. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets.
Covic L; Gresser AL; Kuliopulos A
Biochemistry; 2000 May; 39(18):5458-67. PubMed ID: 10820018
[TBL] [Abstract][Full Text] [Related]
28. C1-inhibitor influence on platelet activation by thrombin receptors agonists.
Tarandovskiy ID; Buehler PW; Karnaukhova E
Clin Appl Thromb Hemost; 2022; 28():10760296221120422. PubMed ID: 35996317
[TBL] [Abstract][Full Text] [Related]
29. Thrombin-induced platelet endostatin release is blocked by a proteinase activated receptor-4 (PAR4) antagonist.
Ma L; Hollenberg MD; Wallace JL
Br J Pharmacol; 2001 Oct; 134(4):701-4. PubMed ID: 11606309
[TBL] [Abstract][Full Text] [Related]
30. PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intact.
Judge HM; Jennings LK; Moliterno DJ; Hord E; Ecob R; Tricoci P; Rorick T; Kotha J; Storey RF
Platelets; 2015; 26(3):236-42. PubMed ID: 24750101
[TBL] [Abstract][Full Text] [Related]
31. Platelet activation via PAR4 is involved in the initiation of thrombin generation and in clot elasticity development.
Vretenbrant K; Ramström S; Bjerke M; Lindahl TL
Thromb Haemost; 2007 Mar; 97(3):417-24. PubMed ID: 17334509
[TBL] [Abstract][Full Text] [Related]
32. PAR4 Antagonism in Patients With Coronary Artery Disease Receiving Antiplatelet Therapies.
Nash J; Meah MN; Whittington B; Debono S; Raftis J; Miller MR; Sorbie A; Mills NL; Nespoux J; Bruce L; Duffin R; Dhaun N; Brittan M; Chao L; Merali S; Kim M; Wang Z; Zhang Y; Jin S; Wang B; Kozinn M; Newby DE
Arterioscler Thromb Vasc Biol; 2024 Apr; 44(4):987-996. PubMed ID: 38357820
[TBL] [Abstract][Full Text] [Related]
33. Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.
Priestley ES; Banville J; Deon D; Dubé L; Gagnon M; Guy J; Lapointe P; Lavallée JF; Martel A; Plamondon S; Rémillard R; Ruediger E; Tremblay F; Posy SL; Guarino VR; Richter JM; Li J; Gupta A; Vetrichelvan M; Balapragalathan TJ; Mathur A; Hua J; Callejo M; Guay J; Sum CS; Cvijic ME; Watson C; Wong P; Yang J; Bouvier M; Gordon DA; Wexler RR; Marinier A
J Med Chem; 2022 Jul; 65(13):8843-8854. PubMed ID: 35729784
[TBL] [Abstract][Full Text] [Related]
34. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand.
Moschonas IC; Kellici TF; Mavromoustakos T; Stathopoulos P; Tsikaris V; Magafa V; Tzakos AG; Tselepis AD
Platelets; 2017 Dec; 28(8):812-821. PubMed ID: 28267389
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic Effects of Combined PAR (Protease-Activated Receptor)-4 Antagonism and Factor Xa Inhibition.
Meah MN; Raftis J; Wilson SJ; Perera V; Garonzik SM; Murthy B; Everlof JG; Aronson R; Luettgen J; Newby DE
Arterioscler Thromb Vasc Biol; 2020 Nov; 40(11):2678-2685. PubMed ID: 32907366
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of protease-activated receptor 4 (PAR4): a review of recent patents (2013-2021).
Yu X; Li S; Zhu X; Kong Y
Expert Opin Ther Pat; 2022 Feb; 32(2):153-170. PubMed ID: 35081321
[TBL] [Abstract][Full Text] [Related]
38. Calcium mobilization and protein kinase C activation downstream of protease activated receptor 4 (PAR4) is negatively regulated by PAR3 in mouse platelets.
Arachiche A; de la Fuente M; Nieman MT
PLoS One; 2013; 8(2):e55740. PubMed ID: 23405206
[TBL] [Abstract][Full Text] [Related]
39. The role of PAR4 in thrombin-induced thromboxane production in human platelets.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Teng CM
Thromb Haemost; 2003 Aug; 90(2):299-308. PubMed ID: 12888878
[TBL] [Abstract][Full Text] [Related]
40. Discovery of 2,3-Dihydro[1,4]dioxino[2,3-
Chen P; Chen C; Zheng Y; Chen F; Liu Z; Ren S; Song H; Liu T; Lu Z; Sun H; Kong Y; Yuan H
J Med Chem; 2024 Apr; 67(7):5502-5537. PubMed ID: 38552183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
